Connect with us

News

Red Eyez: Making CBD accessible to the masses

Red Eyez CBD founder Darshan Patel shares his industry insight with Cannabis Health News along with advice for those looking to get started in the industry

Published

on

Red Eyez: A collection of CBD jars and bottles against a pink and orange sunset

CBD could be a part of everyone’s daily wellbeing routine, but it needs to be affordable first, says founder of Red Eyez CBD, Darshan Patel.

Red Eyez CBD founder Darshan Patel shares his industry insight with Cannabis Health News. The potential benefits of CBD are well reported, and with increasing awareness of the body’s endocannabinoid system (ECS) the world is starting to wake up to the fact that this natural supplement could bring a boost to everyone’s well-being.

There’s just one catch; as well as making the commitment to improve your health, you have to be prepared to make the financial investment.

The founder of UK-based CBD brand Red Eyez, Darshan Patel is trying to change that. He believes that the wealth of CBD products on the market right now are overpriced, with companies driving up price points to make huge profits.

Red Eyez broad-spectrum CBD

When Patel brought his 1000mg broad-spectrum oil to the market after his launch in August 2020 – the ideal starting point he says, for those wanting to try CBD for the first time – it was priced at £19.99.

It’s a stark contrast to the costs of some products out there, which can reach into the triple figures.

“When I started looking at CBD, the first bottle I saw was £119 for 10ml. It put me off straight away,” says Patel.

“That’s a big investment for someone to be able to jump in and use it regularly.”

He continues: “We’re trying to bring CBD products to the market which are affordable to everybody.

READ MORE  CBD products: Understanding the label

“There are a lot of products on the market that are highly-priced, but we’re bringing the same or better quality products for a fraction of that.

“We want to get CBD into people’s cupboards and into their routine as something they use daily, because that’s when they stand to benefit the most.”

Patel wants to make CBD accessible to everyone, not just those with enough disposable income at their fingertips. All of us have an ECS, so we all stand to benefit from its properties.

“People are becoming aware of the fact that we all have ECS, so realistically we need to have access to this supplement,” he says.

“Just as people take vitamins, CBD should be something that is added into your daily routine, but it needs to be affordable first.”

Red Eyez also offers a wide range of products to ensure there is something for everyone.

Red Eyez: A bottle of CBD oil against a yellow background. The bottle is next to the white box

Red Eyez flavours

Its broad spectrum oils come in tempting flavours such as tropical, as well as the cannabis-themed strains of Gelato, Z Skittles, Strawberry Kush and Lemon Skunk which are flavoured with added terpenes.

As well as tinctures, topicals, edibles, bath bombs and CBD-infused coffee, its new range of superfood nootropics capsules have just launched on Amazon.

“Our oils and nootropics are a fun way of taking CBD, people are often wary of the taste but the flavours make it more appealing,” says Patel.

“But we still offer the full spectrum oil which has the original hemp taste, so there is something for every type of consumer.”

READ MORE  “We're asking for quality of life for our children” - medical cannabis report reveals desperation and anger

Business has been good since the site launched last summer, with the impact of the pandemic meaning people are more conscious of their health and wellbeing.

But having a lower-priced product can work against you, admits Patel.

“Some people assume that if our bottle of oil costs £20 and somebody else’s is £60, then it must be lower quality, but people still don’t really know what they are buying when it comes to CBD,” he says.

“It’s important to get the message out there that a higher markup doesn’t necessarily mean a higher quality product.

He adds: “Our average sales may be lower than many in the market, but our return rate is good, people keep coming back because they want to try CBD products and affordability is a big thing.”

Read more: Working out: Could CBD or THC have an effect on your workout?

Epilepsy

CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome

Dr Lyndsey Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

Published

on

Seizure: A row of test tubes containing CBGA oil with a doctors white gloved hand holding one up to the light

Scientists say they have found the ‘Mother of all cannabinoids’ which may help to reduce seizures in Dravet syndrome.

A new study on mice from the University of Sydney found that three acidic cannabinoids found in cannabis reduced seizures in Dravet syndrome, an intractable form of childhood epilepsy.

The three cannabinoids are cannabigerolic acid (CBGA), cannabidivarinic acid (CBDVA), cannabigerovarinic acid (CBGVA). All three but CBGA in particular “may contribute to the effects of cannabis-based products in childhood epilepsy” noted the researchers and were found to potentially have ‘anticonvulsant properties.”

The study marks the first time that three acidic cannabinoids were found to potentially help reduce seizures for Dravet syndrome.

Speaking with Cannabis Health News, the lead author of the study, Dr Lyndsey Anderson, said: “We found that CBGA exhibited both anticonvulsant and pro-convulsant effects. CBGA was more potent than CBD against febrile seizures in a mouse model of Dravet syndrome. We also found that a combination of CBGA and clobazam was more effective than either treatment alone. Additionally, we found that CBGA was anticonvulsant in the maximal electroshock acute seizure model, a model for generalized tonic-clonic seizures.”

She added: “CBGA did, however, present some proconvulsant effects. The frequency of spontaneous seizures in the mouse model of Dravet syndrome was increased with a high dose of CBGA. Also, CBGA was proconvulsant in the 6-Hz acute seizure model, a model of focal, psychomotor seizures.”

Although CBGA shows promise, Dr Anderson also stressed that it needs more research before it can replace CBD. She cautioned that Dravet syndrome patients may still need to proceed with caution.

READ MORE  This CBD hand cream has been hailed as one of the best

“Artisanal cannabis-based products are believed to reduce seizures in Dravet syndrome patients,” she said. “As these oils contain rare cannabinoids like CBGA, it is possible CBGA then contributes to the anticonvulsant effects of these artisanal cannabis oils. However, there were proconvulsant effects observed with CBGA, suggesting that Dravet syndrome patients may need to proceed with caution. The proconvulsant liability of CBGA would need to be addressed before it replaced CBD as an anticonvulsant.”

What is CBGA?

Sometimes referred to as ‘the mother of all cannabinoids,’ CBGA is the precursor molecule to many different cannabinioids including CBD and THC. It is thought to help some diseases such as colon cancer, metabolic disease and cardiovascular disease. It is a non-intoxicating cannabinoid much like CBD.

Dr Anderson explains that more research is needed to explain how the three cannabinoids work together.

“We don’t know how they work together yet,” she said. “We found that CBGA, CBDVA and CBGVA were all individually anticonvulsant against thermally induced seizures in the mouse model of Dravet syndrome. We did not investigate whether a combination of these three cannabinoids would result in a greater anticonvulsant effect than either cannabinoid alone. Future work will definitely explore this possibility.”  

CBGA future research

This isn’t the end of the research into CBGA for Dravet Syndrome. Dr Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

 

She said: “Next on the horizon for this research is to explore whether the anticonvulsant properties of CBDVA and CBGVA translate to other seizure types including spontaneous seizures in the mouse model of Dravet syndrome. Additionally, we have extensively interrogated the anticonvulsant potential of individual cannabinoids and identified ten with anticonvulsant properties.”

READ MORE  How you could help fund medical cannabis treatment for more patients

 

“We are now interested in investigating what happens when we combine these anticonvulsant properties. It remains an open possibility that greater anticonvulsant effects are achieved when the cannabinoids are administered in combination.”

The study was recently published in the British Journal of Pharmacology (DOI: 10.1111/bph.15661)

Continue Reading

Industry

New York regulators vote to allow home grow for medical cannabis patients

The new regulations would allow medical cannabis patients and carers in the state a safe, cost-effective way to access their medication

Published

on

New York: The statue of Liberty against a blue sky and the skyline of New York city

The proposed regulations would allow medical cannabis patients and carers in New York to grow up to six plants, indoors or outdoors, for therapeutic use.

New York cannabis regulators voted unanimously for the proposed regulations which would not only allow qualified patients to grow their own plants.

According to a slide from the Cannabis Control Board presentation, patients would be allowed six plants each but carers with more than one patient,  can “cultivate 1 additional cannabis plant for each subsequent patient.”

The new regulations would impose a duty on patients to ensure no one under the age of 21 can access the plants or any products cultivated from them.

Landlords would also have the option to prohibit their tenants from growing cannabis on their property if they chose. The products must not be processed using anything other than alcohol.

The regulations will now have a 60-day public commentary period before review.

Tremaine Wright, chair of the Cannabis Control Board (CCB) said: “We are proud to present those proposed regulations. The home cultivation of medical cannabis will provide certified patients with a cost-effective means of obtaining cannabis through personal cultivation while creating a set of standards governing the conduct and activities relating to the personal cultivation of cannabis.”

In a press release, the CCB also gave an update on the expungement of cannabis convictions. “Approximately 203,000 cannabis-related charges are presently being suppressed from criminal background searches and are in process of being expunged, adding to the approximately 198,000 records that were expunged as part of the first round of cannabis expungement following legislation enacted in 2019.”

READ MORE  Industry urged not to panic over Home Office stance on CBD

New York recreational market

Earlier this year, New York. It would become the 16th US state to legalise recreational cannabis creating thousands of jobs and tax revenue. The bill was signed into law by Governor Andrew Cuomo in March.

The law would allow for possession of up to three ounces of marijuana for personal use. It would allow licensed dispensaries to sell cannabis products to those over 21.

Neighbouring states who have already legalised marijuana, including New Jersey and Massachusetts, meant that New York citizens were leaving to access cannabis losing tax revenue in the process.

It is expected that home grow for recreational users will follow the proposed regulations for medical cannabis patients but only after the new market is established.

Read more: California governor signs Ryan’s Law to allow medical cannabis use in hospitals

Continue Reading

News

CiiTECH announces new CPD-accredited training course

It aims to support and encourage UK pharmacists, physicians and nurses.

Published

on

Ciitech academy
The course aims to support and encourage UK pharmacists, physicians and nurses.

Cannabis healthcare company CiiTECH has been awarded CPD accreditation for its academy course, which aims to support and encourage UK pharmacists, physicians and nurses.

CiiTECH’s Cannabis Science and Therapeutics course has had tremendous success after launching the course earlier this year.

The new and innovative course offers an interactive digital platform with a 12 chapter syllabus comprising of medical cannabis, CBD knowledge and information, specifically catered for healthcare professionals in the UK.

Industry experts in the UK could potentially face serious challenges if the trainers in question who are both recommending, and dispensing information are not up to the required standards in the field.

People currently working in the industry, such as pharmacy professionals will feel more secure and confident after taking the course. With such an array of knowledge from the experts, they are better able to recommend, treat and understand benefits and causes of their patients.

Besides all the learning and comprehensive information, simple FAQ questions by patients can be simply downloaded to have at hand as an ongoing reference.

The CBD industry is an extremely fast growing market, people are becoming more and more aware of benefits and common usage. It’s said that by 2025 the market in the UK only will be worth over £3 billion.

This means that clinics and pharmacies must be sourcing trustworthy information to their customers.

This course is aimed at filling an education gap in the market, by covering several points in intricate detail, from plant history to dosing, and patient care. A lot of occupations in the UK require an on going learning process each year, with positive results overtime, leading to a greater service in the industry.

“Through years of experience serving UK customers with our portfolio of CBD brands it was abundantly clear that the level of misinformation was enormous and confusing for everyone involved,” says Clifton Flack, CEO and founder of CiiTECH.

“Formal education is always important but with little to no existence in the UK we could not see a better way to help lead the industry than to establish our own online academy and give healthcare professionals the opportunity to not only learn about cannabis therapeutics but to earn further education points at the same time.”

Flack adds: “With the rise in UK cannabis prescriptions and CiiTECH’s long awaited move into the THC medical cannabis arena, now is the time to increase professional education and it is exactly why we have embarked on this education journey. CiiTECH is fast becoming the UK’s one stop shop for all your cannabis needs; research, education, consumer brands.”

CiiTECH collaborated with Medical Cannabis Mentor to produce the course and prepare it for CPD certification.

Joe Dolce, founder and CEO of Medical Cannabis Mentor, comments: “The course synthesises the most up-to-date scientific research and clinical guidelines in an engaging format to help professionals make informed treatment decisions.”

The course can be found on https://cpduk.co.uk/ or for pricing and registration visit:  https://ciitech.academy

CBD and CBG: A black banner saying that the content has been created with sponsors

READ MORE  This CBD hand cream has been hailed as one of the best
Continue Reading

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.